Skip to main content
. Author manuscript; available in PMC: 2021 Dec 7.
Published in final edited form as: Mol Pharm. 2020 Nov 10;17(12):4691–4703. doi: 10.1021/acs.molpharmaceut.0c00983

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Immunochemotherapy reduces tumor burden in vivo. (A) Experimental timeline; animals were randomized and allocated into groups on day 7 prior to treatment, arrows indicate treatment days with vehicle (1% DMSO, 5% tween80, PBS, p.a.), 1mg/kg PLX (p.a.), 1mg/kg PTX (i.v.), and 1 mg/kg PLX (p.a.) + 1 mg/kg PTX (i.v.) combination, experiment was terminated on day 19; (B) ex vivo bioluminescence analysis of tumor burden via ex vivo lung imaging on the terminal day, grid line indicates the baseline flux acquired by imaging of lungs of nontumor bearing animals (n=3); statistical significance was determined using Kruskal Wallis test (*p <0.05), data represented as mean ±SEM (n=9–10). (C) tumor burden assessed by lung weight on the terminal day, grid line indicates the average lung weight of nontumor bearing animals (n=3); statistical significance was determined using One-way ANOVA (*p <0.05, **p <0.01), data represented as mean ±SEM (n=9–10), (D) measurement of body weights represented by percentage changes from day zero (100%) to the terminal day.